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Pancreatic cancer is characterized by expanded stroma with marked fibrosis. In Ijichi et al., we show that inhibiting CXCR2
disrupts tumor-stromal interactions and improves survival of a genetically-engineered mouse model recapitulating
human pancreatic cancer. Targeting CXCLs/CXCR2 axis in the tumor microenvironment might be a potent therapeutic
strategy for pancreatic cancer.
Pancreatic cancer is the fourth leading
cause of cancer death in the United States
and the fifth in Japan.
1,2 It is one of the
most lethal cancers, with five-year survival
rate of less than 5%. Moreover, even with
a successful resection, five-year survival is
still less than 20%. The poor outcome
after resection may be due to the frequent
aggressive character of pancreatic tumor
cells, which are often able to efficiently
invade, disseminate and metastasize.
3
We have established a genetically-
engineered mouse model of pancreatic
ductal adenocarcinoma (PDAC), the most
common type of human pancreatic
cancer, using pancreas epithelium-specific
knockout of TGFβ Type II receptor in
the context of active Kras expression
(Kras
+Tgfbr2KO).
4 This model recapitu-
lated aggressive clinical characteristics and
histological features of human PDAC,
including abundant stromal components
with marked fibrosis (desmoplasia) and
median survival of 59 days.
4
Recently, tumor microenvironment has
been gaining increased attention. A num-
ber of components other than the tumor
cells are involved in the tumor micro-
environment: fibroblasts and a variety of
extracellular connective tissues, macro-
phages, neutrophils, lymphocytes and
other inflammatory and immune cells,
vascular and lymphatic vessels etc.
(Fig.1). Interactions between the tumor
and stromal cells and also between the
stromal components might contribute to
establish a condition in favor of the tumor
cells.
5,6,7 Understanding the underlying
mechanisms might be especially important
for the stroma-rich cancers, like pancreatic
cancer.
In Ijichi et al.,
8 we investigated the
tumor-stromal interaction using our
mouse model. We isolated the PDAC
cells from the Kras
+Tgfbr2KO pancreatic
cancer tissue and mPanIN (mouse pan-
creatic intraepithelial neoplasia) cells from
the Kras alone-activated murine precancer
tissue and screened secreted factors by
using cytokine antibody array. This ana-
lysis revealed that CXC chemokines,
CXCL1, 2, 5 and 16 were produced and
secreted by the PDAC cells at a signific-
antly higher level compared with the
mPanIN cells. CXCL1, 2 and 5 bind the
receptor CXCR2 and CXCL16 is a
ligand of CXCR6. A CXCR2 inhibitor
did not affect in vitro proliferation of the
Kras
+Tgfbr2KO PDAC cells, which indi-
cated that the CXCR2 ligands did not
promote the PDAC cell proliferation
autonomously. We also observed that the
CXCR2 ligands expression in the PDAC
cells was NFkB signal-dependent.
8
We isolated pancreatic fibroblasts, as a
representative of stromal components in
the pancreatic tumor tissue, from the Kras
alone-activated mPanIN tissue. The geno-
typing PCR confirmed that the stromal
fibroblasts did not contain Kras recombi-
nation. CXCR2 mRNA expression was
significantly higher in the pancreatic
fibroblasts than the PDAC cells and
CXCR2 immunohistochemistry showed
relatively prominent staining at the invas-
ive front of the PDAC both in the stroma
and epithelium.
8 Taken together, the
CXCR2 ligands secreted from the PDAC
cells might influence on stromal fibroblasts
and this tumor-stromal interaction could
have a significant impact on PDAC
progression.
Previously, we reported that connective
tissue growth factor (CTGF), a profibrotic
and tumor-promoting factor, was strongly
expressed at the tumor-stromal border
of the Kras
+Tgfbr2KO PDAC tissues,
4
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suggesting an active CTGF-dependent
tumor-stromal interaction. We observed
that the CTGF expression was signifi-
cantly induced when the fibroblasts were
incubated with the CXC chemokines or
conditioned culture media from the
PDAC cells and it was CXCLs/CXCR2
axis-dependent.
8 TGFβ signaling, a well-
known inducer of CTGF expression, was
also required for the induction.
In the subcutaneous tumor grafting
study in vivo, mixed cell tumors injected
with a combination of the PDAC cells
and pancreatic fibroblasts showed a faster
growth compared with the tumors with
the PDAC cells alone, which indicated a
tumor-promoting tumor-stromal interac-
tion. Growth of the mixed cell tumors
showed a significant delay by treatment
with CXCR2 inhibitor or when CXCR2
was knocked down in the fibroblasts.
8
Therefore, the tumor growth might be
highly dependent on the axis of CXCLs
from the PDAC cells/CXCR2 on the
stromal fibroblasts, thus the stromal
CXCR2 can be a potent therapeutic target
rather than epithelial CXCR2 in the
tumor-stromal interaction.
When the Kras
+Tgfbr2KO PDAC mice
were treated with CXCR2 inhibitor
with/without gemcitabine, the CXCR2
inhibitor decreased the tumor volume
compared with the control group through
inhibiting tumor angiogenesis and pro-
longed overall survival significantly.
8
Decreased CTGF expression was also
observed in the treated PDAC tissues.
Gemcitabine, a standard chemotherapeu-
tic agent of PDAC, also demonstrated a
decrease of tumor volume and prolonged
overall survival, however, it did not change
the tumor angiogenesis, which meant a
distinct mode of action. The CXCR2
treatment also demonstrated a decrease of
macrophage and neutrophil infiltration
in the PDAC tissue, suggesting a broad
modification of the tumor microenviron-
ment. In summary, in the Kras
+Tgfbr2KO
PDAC, that can recapitulate human
PDAC, CXC chemokines are characterist-
ically produced and secreted from the
PDAC cells into the tumor microenviron-
ment, which bind CXCR2 on the stromal
fibroblasts and induce CTGF expression
and tumor angiogenesis, resulting in
PDAC progression (Fig.1). When the
CXCLs/CXCR2 axis is blocked, the
tumor-promoting tumor-stromal inter-
action is abrogated, leading to decrease of
the tumor volume and prolonged overall
survival of the mice. This is a distinct
mechanism of anti-cancer effect from that
of conventional chemotherapeutic agents.
Although we focused on the CXCLs/
CXCR2 and CTGF using PDAC cells
and fibroblasts in this study, there also
seem other components and factors
involved in the tumor-stromal interactions
to be further investigated in the PDAC
microenvironment. Pursuing the optimal
combination of chemotherapeutic agents
targeting directly PDAC cells and modu-
lating agents of the tumor microenviron-
ment might provide a promising therapy
for PDAC (Fig.1).
Figure1. Modulating tumor microenvironment in combination with conventional chemotherapy
might be a promising therapeutic strategy for pancreatic cancer. Tumor microenvironment of
the pancreatic ductal adenocarcinoma (PDAC) contains abundant stromal components other than
the tumor cells (PDAC cells): fibroblasts and extracellular matrix, inflammatory and immune cells
like macrophage, neutrophil, lymphocytes, and vasucular and lymphatic vessel systems including
endothelial cells and pericytes etc. A wide variety of interactions of these components constitute
an environment in favor of the PDAC cells, partly through tumor angiogenesis and an escape from
the immune surveillance. The Kras
+Tgfbr2KO PDAC cells secrete several CXC chemokines into
the microenvironment and activate CXCR2 on the stromal fibroblasts. In response, the fibroblasts
produce CTGF, which contributes to promote tumor angiogenesis. The CXC chemokine production
from the PDAC cells is NFkB signaling-dependent and the CTGF expression from the fibroblasts is
TGFb signal-dependent. Therefore, to inhibit this tumor-stromal interaction, CXC chemokines and
the receptor CXCR2, CTGF, NFkB signal in the PDAC cells and TGFb signal in the fibroblasts can be
therapeutic targets. The PDAC cells also secrete other important factors than the CXC chemokines,
the fibroblasts also produce other factors than CTGF in response and other stromal components
also respond to the stimuli from the PDAC cells, which remain to be further investigated.
Since conventional chemotherapy like gemcitabine targets directly tumor cells, a combination of
the inhibition of tumor-stromal interaction and the chemotherapy might provide a more effective
therapeutic option.
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